Stereotactic radiotherapy for metastatic kidney cancer

A paper published in the European Journal of Cancer earlier this month reports on the experience of six French hospitals with stereotactic radiotherapy (SRT) for metastatic renal cell carcinoma (RCC) between 2008 and 2015 . This retrospective study showed a 12-month local control rate of metastases of 82.9%. Twenty-five percent of patients with oligometastatic disease […]

read more

First patient to undergo proton beam therapy in the UK

The first patient in the UK to undergo proton beam therapy was treated for prostate cancer at the Rutherford Cancer Centre in Newport, South Wales, in April. This treatment “opens up a new frontier for treatment in the UK”, said his consultant. The Rutherford Cancer Centre is the only clinic in the UK where high-energy […]

read more

First-line tivozanib approved for use in NHS Scotland

We are delighted that the Scottish Medicines Consortium (SMC), which reviews newly licensed medicines, has published advice recommending tivozanib (Fotivda) as a new first-line treatment option for people with advanced renal cell carcinoma (RCC) for use within NHS Scotland. Tivozanib, a tyrosine kinase inhibitor, was accepted following consideration through the SMC’s Patient and Clinician Engagement (PACE) process, which is […]

read more

Prevalence of hereditary mutations in kidney cancer patients more than first thought

A recent study published in JAMA Oncology last week examined the prevalence of hereditary mutations in renal cell carcinoma (RCC) associated genes to identify the clinical and pathological factors associated with these mutations. Identification of patients with hereditary RCC is important for cancer screening and, in patients with advanced disease, for treatment and management of […]

read more

Should the primary kidney tumour be treated in metastatic disease?

Dr Gennady Bratslavsky gave a presentation at a urology symposium in Israel last week discussing the question of whether the primary tumour should be treated in metastatic renal cell carcinoma (RCC). The outline of his presentation included: Current guidelines for metastatic RCC The rational behind cytoreductive nephrectomy (CN) Historical evidence supporting current guidelines A discussion […]

read more

Personalised management of advanced kidney cancer

A recent article published in the 2018 American Society of Clinical Oncology Educational Book, summarises the advances made towards personalised management of advanced renal cell carcinoma (RCC). The researchers suggest that “Individualised care using predictive biomarkers is central to the treatment of other advanced malignancies,” and “The elucidation of predictive factors is an unmet need in metastatic […]

read more
Showing 1 to 6 of 401 results
  TOP